Enviro-Hub (L23) H2 2025 earnings summary

Executive summary

• FY2025 continuing-operations revenue rose 31% to $39.1m, with profit for the year of $1.6m; e-waste recycling supplied 94% of revenue.

• Continuing operations returned to a $1.6m pre-tax profit from a $24.3m loss in FY2024, which included substantial healthcare-related impairments.

• Operational focus included integrating recycling capabilities and repositioning R Pharmacy toward premium retail, while managing commodity-price and supply-chain volatility.

Financial highlights

• Continuing-operations revenue increased 31% to $39.114m from $29.957m; gross profit rose 10% to $7.981m from $7.287m.

• Continuing-operations profit before tax was $1.620m versus a $24.268m loss; continuing profit after tax was $1.561m versus a $24.036m loss.

• Total profit was $1.567m, but loss attributable to owners was $655k; the difference reflects $2.222m profit attributable to non-controlling interests.

• Other income was $7.011m, including a $4.696m investment-property fair-value gain and $1.012m foreign-exchange gain; FY2024 included $6.066m compensation receivable from a former subsidiary director.

• Operating cash flow was $7.069m, up from $1.868m; cash and cash equivalents were $19.243m at year-end, versus $12.419m.

Outlook and guidance

• E-waste recycling is expected to maintain growth momentum over the next 12 months, supported by rising e-waste volumes, structured recycling demand and Singapore’s expanding EPR framework.

• Singapore plans e-waste bins at all community centres by H1 2026; light-industrial and warehouse rents are projected to rise up to 2.0% YoY in 2026.

• R Pharmacy is exploring entry into Johor in 2026 and plans to continue premium positioning and differentiated marketing.

• Energy-price volatility and inflation may raise costs and prompt customer inventory reductions or price requests; management expects no material profitability or going-concern impact.